TSS
IRLA

Two Sigma Securities’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Two Sigma Securities’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60
Closed -$19.8K – 1890
2025
Q2 		$19.8K Buy
+60
New +$13.7K ﹤0.01% 1210
2024
Q1 		– Sell
-60
Closed -$12.6K – 3525
2023
Q4 		$12.6K Buy
+60
New +$12K ﹤0.01% 2791
2022
Q1 		– Sell
-69
Closed -$174K – 2431
2021
Q4 		$174K Buy
+69
New +$421K 0.01% 1104

Other funds holding IRLA

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Two Sigma Securities's IRLA Position: Q3 2025 in Review

Two Sigma Securities sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q3 2025, closing a stake of 60 shares — an estimated $19.8K sold.

Two Sigma Securities first reported a position in IRLA in Q4 2021 and held it in 3 quarters. The position peaked at $174K in Q4 2021. 41 funds tracked by Wall St. Rank hold IRLA as of Q3 2025.

  • Two Sigma Securities reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Securities sold 60 IRulya Therapeutics Inc. Common Stock shares in Q3 2025, an estimated $19.8K.
  • Two Sigma Securities first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Two Sigma Securities's IRulya Therapeutics Inc. Common Stock position peaked at $174K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.